| Product Name | Sitaxsentan sodium (Synonyms: IPI 1040 sodium; TBC11251 sodium) |
|---|---|
| CAS | 210421-74-2 |
| Formula | C18H14ClN2NaO6S2 |
| MW | 476.89 |
| Appearance | Light yellow to yellow powder |
| Storage condition | 4°C, sealed storage, away from moisture |
| Size | Availability | Price(USD) | VIP Price (USD) | Quantity | |
|---|---|---|---|---|---|
|
There is no price information at the moment, you can send an inquiry,and we will reply to you as soon as possible. |
|||||
| Product Name | Sitaxsentan sodium (Synonyms: IPI 1040 sodium; TBC11251 sodium) |
|---|---|
| CAS | 210421-74-2 |
| Formula | C18H14ClN2NaO6S2 |
| MW | 476.89 |
| Appearance | Light yellow to yellow powder |
| Storage condition | 4°C, sealed storage, away from moisture |
Sitaxsentan sodium (IPI 1040 sodium; TBC11251 sodium) is a potent, selective and orally activeendothelin A receptor (ETA) antagonist with an IC50 of 1.4 nM and a Ki of 0.43 nM. Sitaxsentan sodium exhibits an IC50 for the ETB receptor of as high as 9800 nM. Sitaxsentan sodium inhibits ET-1-induced phosphoinositide turnover. Sitaxsentan sodium can significantly alleviate pulmonary arterial hypertension (PAH) symptoms. Sitaxsentan sodium can be used for the study of PAH.
PMID: 20628435 DOI: 10.1139/Y10-060
PMID: 10799286 DOI: 10.1006/pupt.2000.0237
Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
PMID: 20693396 DOI: 10.1152/ajpheart.00418.2010